Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Earnings Call Transcript pertaining to the audited Financial Results of the Company for quarter and year ended March 31, 2023. The same is also available on the Company's website at https://www.sequent.in/pdf/financial/2022- 2023/Q4/SequentSci-Earnings-May24-2023.pdf
26-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 30 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of advertisement published on May 25, 2023, in 'Financial Express' and 'Mumbai Lakshadeep' newspapers providing Extracts of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2023.
25-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings call and earnings presentation made on May 24, 2023, on Audited Financial Results (Consolidated and Standalone) of the Company for the quarter and year ended March 31, 2023, is available on the Company's website
24-05-2023

Sequent Scienti Consolidated March 2023 Net Sales at Rs 366.67 crore, down 4.44% Y-o-Y
24-05-2023

Sequent Scientific Results Earnings Call for Q4FY23

 Conference Call with Sequent Scientific Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
24-05-2023

SeQuent Scientific dips 2% after Q4 loss

 The animal health company posted a net loss of Rs 92.43 crore for the quarter ended March.
24-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 In terms of Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended March 31, 2023.
23-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023.
23-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On May 23, 2023 Along With Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended March 31, 2023

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 3. The Board has not recommended any dividend for F.Y. 2022-23.
23-05-2023
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2023 Along With Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended March 31, 2023

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. In this regard, kindly find enclosed the following: 1. Audited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion. 2. Audited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023 with an unmodified opinion.
23-05-2023
Next Page
Close

Let's Open Free Demat Account